Researchers have systematically evaluated the efficacy and safety of Lixisenatide ( Lyxumia ) in patients with type 2 diabetes mellitus.
Fourteen multicenter randomized controlled trials involving 11,947 patients were eligible for inclusion.
Compared to placebo, Lixisenatide could more significantly reduce the level of HbA1c ( weighted mean difference, WMD=-0.44; 95% confidence interval [ CI ] [ -0.55,-0.33 ] ), and a higher proportion of Lixisenatide-treated patients achieved the HbA1c level of less than 7.0% ( relative risk, RR = 1.89, 95% CI [ 1.75-2.03 ] ) and less than 6.5% ( RR = 3.03, 95% CI [ 2.54-3.63 ] ) than the placebo-treated patients.
Lixisenatide was also associated with a significant reduction in fasting plasma glucose and 2-hour postprandial plasma glucose levels.
The risks for any adverse events, gastrointestinal adverse events, and symptomatic hypoglycemia significantly increased in the Lixisenatide-treatment group compared to those in the placebo group.
However, lixisenatide did not increase the risks of serious adverse events, death, or severe hypoglycemia.
In conclusion, Lixisenatide was more effective than placebo in patients with type 2 diabetes mellitus, and the mild-to-moderate adverse events were found to be tolerated during the follow-up. ( Xagena2018 )
Wei ZG et al, Medicine ( Baltimore ) 2018;97(51):e13710. doi: 10.1097/MD.0000000000013710.